Unknown

Dataset Information

0

Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.


ABSTRACT: Introduction: Cancer-directed immunotherapies are transforming the landscape in oncology as new and exciting therapies move from the laboratory to the bedside. Chimeric antigen receptor T (CAR-T) cells are one of these novel therapies, demonstrating impressive efficacy against B-cell malignancies. With the development of new therapies, it is not uncommon to identify new and unanticipated toxicities. CAR-T cells cause unique toxicities not typically found with traditional cytotoxic chemotherapy or small molecule inhibitors. Areas covered: CAR-T cell associated toxicities include cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES), alternatively known as immune effector cell-associated neurotoxicity syndrome (ICANS). Prompt identification and management of CRS and CRES are imperative for the prevention of life-threatening complications of these innovative therapies. This literature review describes the seminal trials of CD19-directed immunotherapy and the pathophysiology and management of the toxicities found with CAR-T cells. In addition, the use of the interleukin-6 receptor antibody tocilizumab for CRS is reviewed. Expert opinion: This review describes the recommended management of CRS and CRES and examines the current limitations in management. Alternative therapies for the treatment of CAR-T cell related toxicities are also explored. Furthermore, the review proposes future directions for research.

SUBMITTER: Kotch C 

PROVIDER: S-EPMC7936577 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.

Kotch Chelsea C   Barrett David D   Teachey David T DT  

Expert review of clinical immunology 20190620 8


<b>Introduction</b>: Cancer-directed immunotherapies are transforming the landscape in oncology as new and exciting therapies move from the laboratory to the bedside. Chimeric antigen receptor T (CAR-T) cells are one of these novel therapies, demonstrating impressive efficacy against B-cell malignancies. With the development of new therapies, it is not uncommon to identify new and unanticipated toxicities. CAR-T cells cause unique toxicities not typically found with traditional cytotoxic chemoth  ...[more]

Similar Datasets

| S-EPMC10834881 | biostudies-literature
| S-EPMC7940756 | biostudies-literature
| S-EPMC9198280 | biostudies-literature
| S-EPMC5452983 | biostudies-literature
| S-EPMC7498115 | biostudies-literature
| S-EPMC7893957 | biostudies-literature
| S-EPMC5701525 | biostudies-literature
| S-EPMC7485001 | biostudies-literature
| S-EPMC8525234 | biostudies-literature
| S-EPMC8291836 | biostudies-literature